Search results
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
Zacks via Yahoo Finance· 11 hours agoShares of this drugmaker have returned -10% over the past month versus the Zacks S&P 500 composite's...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 11 hours agoSales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition from cheaper...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 12 hours agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 21 hours agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie
AbbVie (ABBV) Could Be a Great Choice
Zacks via Yahoo Finance· 1 day agoDividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?...
AbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
Zacks via Yahoo Finance· 5 days agoAbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the...
AbbVie Inc (ABBV) Q1 2024 Earnings: Adjusted EPS Tops Estimates
Guru Focus· 5 days agoOn April 26, 2024, AbbVie Inc (ABBV, Financial) released its 8-K filing, detailing the financial outcomes for the first quarter ended March 31, 2024. The pharmaceutical ...
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Motley Fool via Yahoo Finance· 5 days agoThose sales figures would be more than twice the drugs' totals last year. Those are just two of the...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 6 days agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
Better Dividend Stock: AbbVie or Johnson & Johnson?
Motley Fool via Yahoo Finance· 4 days agoLast year, the company earned approval for Epkinly, a new cancer medicine that could reach peak sales of $3 billion in the U.S. alone, according to some...
